黄素营养药 (Eriomin®) 减轻糖尿病前期肠道失调症:双盲随机对照试验
Fernanda M M Ramos1, Carolina B Ribeiro1, Thais B Cesar1
1Graduate Program in Food, Nutrition and Food Engineering Sao Paulo State University (UNESP) Araraquara Brazil.
Food science & nutrition
|November 16, 2023
概括
类黄类补充剂Eriomin®通过改变肠道微生物群组成,增加有益细菌和提高GLP-1水平,改善了糖尿病前期患者的血糖控制.
科学领域:
- 营养科学 营养科学
- 微生物学 微生物学
- 内分泌学 在内分泌学.
背景情况:
- 类植物中的一种黄类化合物埃里奥西特林 (Eriocitrin) 显示出在治疗高血糖症和改善糖尿病生物标志物方面具有潜力.
- 肠道微生物的新陈代谢影响能量生产和血糖控制通过短链脂肪酸.
- 前糖尿病的特点是葡萄糖代谢受损,通常与肠道失调有关.
研究的目的:
- 评估Eriomin®,一种富含埃里奥西特林的营养药对糖尿病前期患者肠道微生物群的影响.
- 评估Eriomin®对糖尿病前期血糖控制和相关生物标志物的影响.
主要方法:
- 一个为期12周的随机化,安慰剂对照试验,涉及糖尿病前期患者.
- 患者每天接受200毫克Eriomin®或安慰剂.
- 用便样本的16SrRNA测序分析了肠道微生物组成.
主要成果:
- 服用Eriomin®补充剂导致高血糖症降低了6%,GLP-1水平增加了22% (p < .05).
- 观察到肠道微生物群的显著变化,包括Firmicutes和Lachnospiraceae的减少,以及Ruminococcaceae的增加.
- 发现与降低高血糖的积极相关的Blautia属被Eriomin®降低.
结论:
- 营养药物Eriomin®调节肠道微生物群,减少与失能相关的微生物,增强有益细菌.
- 微生物群中的埃里奥西特林驱动的变化与改善的血糖水平和糖尿病前期患者的GLP-1产量增加有关.
- 埃里奥明®通过肠道微生物群干预,显示出作为治疗糖尿病前期管理的治疗剂的潜力.
关键词:
埃里奥明® (Eriomin®) 是一种可怕的药物.临床试验临床试验临床试验临床试验临床试验埃里奥西特林是一种营养药物.肠道失生症是指肠道失生症.的黄类黄类化合物微生物群 (16S rRNA) 的存在在糖尿病前期.更多相关视频
相关概念视频
Drugs for Treatment of Diarrhea-Predominant IBS
183
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
183
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
337
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
337
Bacterial Flora of the Large Intestine
473
The gut microbiome is formed by a vast and diverse community of bacteria that colonizes our large intestine. These bacteria start residing in the gut from birth and continue diversifying throughout life, influenced by factors such as diet, lifestyle, and stress. The gut bacterial community also includes bacteria from food and those that enter the colon through the anus.
The normal gut flora of the colon plays a critical role in generating essential vitamins such as vitamins K, B5, and B7.
The normal gut flora of the colon plays a critical role in generating essential vitamins such as vitamins K, B5, and B7.
473
Drugs for Treatment of Constipation-Predominant IBS
180
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
180
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
182
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
182


